Priovant Launches New Brepocitinib Trial for LPP Hope
Priovant has begun enrolling a seamless Phase 2b/3 trial of brepocitinib in lichen planopilaris (LPP), with first patients dosed...
The GLP-1 Pill Just Broke Every Obesity Trial Playbook
The FDA's approval of oral orforglipron for obesity isn't just a formulation win — it's a structural disruption to...
Promising New Eye Pain Trial Begins With First Patient Dosed
Pelthos Therapeutics has dosed the first patient in a Phase 1b/2a study of CT2000, a topical NaV1.7 inhibitor eye...
Tarsus Doses First Patient in Lyme Disease Prevention Trial
In earlier proof-of-concept work, a single oral dose of TP-05 (lotilaner) produced more than 90% tick mortality within 24...
Adcytherix Launches Phase 1 Trial, Strengthens Leadership
Adcytherix has dosed the first patient in a Phase 1a/b study of ADCX-020, an exatecan‑derived topoisomerase I inhibitor antibody‑drug...
Pheast Therapeutics Advances New Cancer Drug to Phase 1b Trial
Pheast Therapeutics has dosed the first patient in the Phase 1b combination portion of its ongoing Phase 1 study...
Actinogen Commences Xanamia Alzheimer’s Open-Label Trial
No efficacy data yet. Actinogen has initiated the open-label extension of its XanaMIA pivotal program in Alzheimer’s disease, dosing...
The EMA’s Virtual Control Group Gambit Could Redraw the Map for Pivotal Trial Design
The EMA has opened consultation on a draft qualification opinion for virtual control groups — a methodology that, if...
The GLP-1 Mood Signal Is Real — But So Is the Psychiatric Worsening Risk
A pattern I’ve been tracking across my dual-diagnosis patient panel this year: the patients who come in asking about...
The Trial That Should Rewrite the Rare Disease Playbook — But Probably Won’t
AstraZeneca's Phase 3 benralizumab trial in hypereosinophilic syndrome just delivered one of the cleanest efficacy signals in rare disease...